相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer
Nassim Ghorbanmehr et al.
PROSTATE (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
Fumihiko Urabe et al.
CLINICAL CANCER RESEARCH (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The expression of miR-375 in prostate cancer: A study based on GEO, TCGA data and bioinformatics analysis
Simin He et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer
Michael T. Schweizer et al.
PROSTATE (2019)
Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes
Sangiliyandi Gurunathan et al.
CELLS (2019)
Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer
Chiang-Ching Huang et al.
CANCERS (2019)
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Vincenza Conteduca et al.
EUROPEAN UROLOGY (2019)
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove et al.
EUROPEAN UROLOGY (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
Takayuki Sumiyoshi et al.
SCIENTIFIC REPORTS (2019)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients
Lee-Ann Tjon-Kon-Fat et al.
PROSTATE (2018)
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer
Heather H. Cheng et al.
PROSTATE (2018)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Niven Mehra et al.
EUROPEAN UROLOGY (2018)
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer
Sarah Q. To et al.
EUROPEAN UROLOGY (2018)
Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition
Pawel Porzycki et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12
Dong Xue et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
Glenn Heller et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer
Benjamin L. Maughan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
J.S. de Bono et al.
ANNALS OF ONCOLOGY (2017)
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer
L. A. Selth et al.
ONCOGENE (2017)
Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions
R. J. Hendriks et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression
Ronghao Wang et al.
EUROPEAN UROLOGY (2017)
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Bram De laere et al.
EUROPEAN UROLOGY (2017)
Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
Christof Bernemann et al.
EUROPEAN UROLOGY (2017)
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
Anna Katharina Seitz et al.
EUROPEAN UROLOGY (2017)
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
Marzia Del Re et al.
EUROPEAN UROLOGY (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Tilman Todenhoefer et al.
JOURNAL OF UROLOGY (2017)
The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice
Irene V. Bijnsdorp et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
Hui-Ming Lin et al.
BRITISH JOURNAL OF CANCER (2017)
The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment
Yanping Gao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Oscar Reig et al.
EUROPEAN UROLOGY (2016)
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2016)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
Leander Van Neste et al.
EUROPEAN UROLOGY (2016)
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
Yuan Wang et al.
MOLECULAR CANCER (2016)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar et al.
NATURE MEDICINE (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan et al.
JAMA ONCOLOGY (2016)
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
S. Salvi et al.
BRITISH JOURNAL OF CANCER (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)
Dan Robinson et al.
CELL (2015)
Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer
Gisele H. J. M. Leyten et al.
CLINICAL CANCER RESEARCH (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Xiaoyi Huang et al.
EUROPEAN UROLOGY (2015)
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Wendy Onstenk et al.
EUROPEAN UROLOGY (2015)
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer
Alexandra Kienel et al.
JOURNAL OF UROLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
Mary-Ellen Taplin et al.
JAMA ONCOLOGY (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
Brian D. Kelly et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Eddy J. Chen et al.
CLINICAL CANCER RESEARCH (2015)
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
H-M Lin et al.
BRITISH JOURNAL OF CANCER (2014)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
John R. Prensner et al.
LANCET ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy
Qizhi Zheng et al.
PROSTATE (2014)
KLK3, PCA3, and TMPRSS2-ERG Expression in the Peripheral Blood Mononuclear Cell Fraction From Castration-Resistant Prostate Cancer Patients and Response to Docetaxel Treatment
Siebren Dijkstra et al.
PROSTATE (2014)
miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression
Claire Corcoran et al.
PROSTATE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
Mary Nakazawa et al.
HORMONES & CANCER (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer
Shancheng Ren et al.
EUROPEAN JOURNAL OF CANCER (2013)
PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study
Marc C. Gittelman et al.
JOURNAL OF UROLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
Simpa S. Salami et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Epithelial Cell Adhesion Molecule-positive Circulating Tumor Cells as Predictive Biomarker in Patients With Prostate Cancer
Robert J. Amato et al.
UROLOGY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Changes in circulating microRNA levels associated with prostate cancer
R. J. Bryant et al.
BRITISH JOURNAL OF CANCER (2012)
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings
Shancheng Ren et al.
CELL RESEARCH (2012)
MicroRNA profiling: approaches and considerations
Colin C. Pritchard et al.
NATURE REVIEWS GENETICS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes
Alessia Gallo et al.
PLOS ONE (2012)
Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer
Luis Resel Folkersma et al.
UROLOGY (2012)
MicroRNA degradation and turnover: regulating the regulators
Zhuo Zhang et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2012)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer
Oscar B. Goodman et al.
CLINICAL GENITOURINARY CANCER (2011)
TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Daniel C. Danila et al.
EUROPEAN UROLOGY (2011)
Circulating miRNAs are correlated with tumor progression in prostate cancer
Jan C. Brase et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
Rong Hu et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2010)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer
Takatsugu Okegawa et al.
JOURNAL OF UROLOGY (2008)
Oldest North American primate
P. D. Gingerich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Leonard S. Marks et al.
UROLOGY (2007)
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
Jack Groskopf et al.
CLINICAL CHEMISTRY (2006)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release
M Stroun et al.
CLINICA CHIMICA ACTA (2001)
分享论文
